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Background: Functional tricuspid regurgitation (TR) is not uncommon in patients who require mitral valve (MV) surgery for severe 
mitral regurgitation (MR), and progression of TR late after surgery has been noted in significant numbers of patients without tricuspid 
annuloplasty (TAP). The purpose of this prospective study was to evaluate the outcome of a strategy in patient selection and size selection 
of a prosthetic ring for TAP in patients undergoing MV repair for severe MR.
methods: A total of 167 patients were underwent MV repair for severe MR from July 2007 to March 2010 in our institution. TAP was 
indicated for patients with one of the following conditions which represent tricuspid annular dilatation; 1) TR ≥ moderate, 2) history of right 
heart failure, 3) atrial fibrillation, 4) pulmonary hypertension. The target size of tricuspid annulus was designed to normal systolic size from 
the patient’s body surface area (BSA). Serial echocardiographic studies were performed preoperatively, at discharge, 1 and 3-year after 
surgery.
results: MV repair was successfully performed in all cases. There were 93 patients (56%) who required TAP (group A), whereas TAP was 
not indicated for 74 patients (44%, group B). The rate of TR ≥ moderate was similar between the groups at discharge, 1 and 3-year after 
surgery (A vs B, 1.1% vs 0.0%, P=0.27; 5.4% vs 2.7%, P=0.38; 6.5% vs 6.8%, P=0.94, respectively). Besides, there were no significant 
differences in freedom from the composite of all cause death, recurrent severe MR and redo surgery at 3-year between the groups (A vs B, 
93% vs 98%, P=0.12).
conclusion:  Patient selection for TAP considering not only the grade of TR but clinical signs representing tricuspid annular dilatation is 
feasible at the time of MV repair. TAP targeting a normal systolic size considering BSA is simple and reproducible procedure.
